PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
|Articles|January 25, 2007
NEW PRODUCT DEVELOPMENT IN THE CHEMICAL INDUSTRY
NEW PRODUCT DEVELOPMENT IN THE CHEMICAL INDUSTRY
Advertisement
Optimising innovation through collaboration and strategic resource management
21 & 22 February 2007, Hilton Amsterdam
E.N.G's 2nd senior executive summit with leading speakers from: Arkema, BASF, Borealis, Celanese, Ciba Specialty Chemicals, Clariant, DSM, Degussa, Delft University of Technology, DOW Chemical, DOW Corning, Kemira, Huntsman and SINTEF Group
Attend this unique summit to hear international experts speak on:
- Developing new products through strategic collaboration and partnerships
- Successful R&D investments in the Far East
- Implications of REACH regulation on product innovation
- Developing new products and processes through innovative technologies
Register now to strategically position your company to take advantage of current innovations within the industry.
For further information and to register:
Contact: Ken Gillings
Tel: +31 (0)20 305 0950 ext 35
Fax: +31 (0)20 305 0970
Email:
Website:
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement